STUDboardsPlay · Research · Self · Fit · Money · Learn · Study · Plan · Token STUDtokenOptional

STUDresearch · Peptide

CJC-1295

Also known as

CJC-1295 with DAC · CJC-1295 no DAC · CJC-1295 without DAC · Mod GRF 1-29 · Modified GRF 1-29 · DAC:GRF · DAC:GRF (ConjuChem) · CJC1295 · CJC 1295 · CJC-1295 DAC · tetrasubstituted GRF 1-29

Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.

Open in the directory ↗
Peptide Lots of talk Systemic Subcutaneous Growth hormone axis

Systemic — raises circulating GH/IGF-1 via pituitary GHRH-receptor stimulation; not a local inject-site healing peptide.

What people say CJC-1295 labels cover albumin-binding DAC and short-acting Mod GRF 1-29 sold as “no-DAC.” People discuss sleep, recovery and GH/IGF-1, often with ipamorelin.DAC and no-DAC do not share one amount, frequency or half-life. Doses people talk about
DAC — weekly-style reports1–2 mg per injection

Usually once weekly; some describe twice weekly. Other charts describe a distinct lower 300–600 mcg per injection once or twice weekly.

No-DAC / Mod GRF reports100–300 mcg per injection

Accounts describe 1–3 times daily. Combination notes separately name 100/100 or 200/200 mcg of no-DAC and ipamorelin; each component matters.

These are community amounts, not equivalent formulations or a dose ladder. Body-weight-based DAC trial details remain below.

Half-life & effect duration

Half-life in the body
  • With DACAbout 6–8 days
  • No DAC / Mod GRF · common community estimateAbout 25–30 minutes
  • Other community guidesAbout 1–2 hours
Felt duration people report
  • Head rush · combination accountStarted about 2 minutes after use; duration unspecified
  • Sleep / restfulnessAll-day restfulness, worse sleep, or little change across a 6-week combination run
Timing context & sources
How it may feel Reports include little acute change, restfulness, worse sleep or a brief head rush when no-DAC is added to ipamorelin.
Cycles people discuss No-DAC plus GHRP discussions describe 8–12 weeks and sometimes 5-on/2-off; DAC accounts describe weekly-style use over months. Timing No-DAC appears in bedtime, morning-fasted and repeated daily routines. DAC appears in weekly-style community use and weekly or 14-day study schedules. Stacks CJC no-DAC + Ipamorelin: Default dual stack and the most common premixed blend on research markets; 1:1 mcg pulses 1–3× daily. Access talk 2026 shelves: some 503A pharmacies still fill (risk-tolerance talk), wellness blends labeled “CJC-1295” that usually mean no-DAC, and RUO DAC vs no-DAC vials. Ask which molecule, not just the brand string. Labs people mention IGF-1 is the DAC scoreboard in those threads — multi-day elevation is what Teichman-style PK would predict; no-DAC bedtime pulses may barely move a morning trough. Watch for Water retention / edema: Transient puffiness (hands, face, ankles) or softer look — more discussed on DAC and higher cumulative GH/IGF-1 exposure.
Related
IpamorelinSermorelinTesamorelinGHRP-2GHRP-6

Tap a line to jump into the full notes. Research only — may be wrong.

Timing context & sources

Half-life in the body

With DAC: about 6–8 days in a human subcutaneous study.

This applies to the long-acting DAC form. GH and IGF-1 responses lasted on different clocks; they are not a measure of how long someone feels an effect.

Teichman's single-dose estimates were 5.8–8.1 days; the multiple-dose study gave 5.4–9.2 days. Industry-sponsored, short studies in healthy adults, not athletic outcomes or indefinite-use safety. No-DAC/Mod GRF is not interchangeable.

Half-life in the body

No-DAC / Mod GRF: around 30 minutes is a community estimate, not a human clearance measurement verified here.

The DAC paper does not establish that number for no-DAC products. Keep the two formulations separate.

The thread repeats a half-life figure without an underlying PK method. It supports the existence of the claim, not numerical accuracy, dosing frequency or safety.

  • CJC with and without DAC — community discussion (opens in a new tab)OP repeats 30-minute no-DAC estimate; tylersl14 reports all-day wellbeing, then discusses ipamorelin and both CJC forms in the follow-up.Relevant post/comments reviewed. Repeated PK number has no method; the felt account is first-person but formulation/stack attribution is unresolved. Other commenters' safety claims are not adopted.

Felt duration people report

Accounts range from a head rush about two minutes after adding no-DAC to ipamorelin, to all-day restfulness, worse sleep after adding 100 mcg no-DAC, or little obvious sleep change across six weeks of a 100/100 mcg combination.

The head-rush account gives about two minutes to onset, not its duration. The all-day account discusses several forms and stacks, so it cannot define a CJC-only clock.

These accounts do not establish a per-dose duration or prevalence. Stacks and unverified products confound attribution; one later reply allows slight, uncertain sleep improvement.

What people say 13

  • Sleep depth: Deeper / more restorative sleep frequently reported, especially bedtime no-DAC + GHRP on empty stomach. forum
  • Vivid dreams: Common early signal when dosing pre-bed; used as a crude “it landed” marker. anecdote
  • Recovery: Easier multi-session training recovery after several weeks — heavily confounded by sleep, calories, and stacks. forum
  • Body recomp assist: Gradual lean-mass support and softer fat-loss edge over months, not a rapid cut drug. forum
  • Skin / fuller look: Some report better skin turgor or “fuller” look — can overlap water retention from GH/IGF-1. anecdote
  • GHRP synergy: Stacked with Ipamorelin (or older GHRP-2/6) for larger combined GH pulses than either alone — the dominant community thesis. forum
  • No-DAC preference: Users wanting natural-style sharp pulses and better GHRP stack timing favor no-DAC / Mod GRF + frequent GHRP over weekly DAC. forum
  • DAC preference: Users wanting 1–2 pins/week and steadier IGF-1 elevation accept flatter GH exposure and more water-retention talk. forum
  • Vs sermorelin: Discussed as more DPP-IV-resistant / longer per-pulse activity than unmodified GRF 1-29; sermorelin has more clinic branding, Mod GRF/CJC more forum culture. forum
  • Vs exogenous GH: Marketed in forums as “stimulate your own GH” with pituitary feedback still in play — outcomes still far below high-dose rGH claims. forum
  • 2025–26 pulse vs bleed still the fork: No-DAC + GHRP bedtime for sleep/pulse lore; DAC for fewer pins / steadier IGF-1 — water talk louder on DAC. forum
  • DAC IGF-1 elevation (clinical): Teichman et al. 2006 — single subq DAC doses produced ~2- to 10-fold mean GH increases lasting ≥6 days and ~1.5- to 3-fold IGF-I lasting ~9–11 days; multi-dose use kept mean IGF-I above baseline up to ~28 days. trial
  • Pulsatility preserved (clinical): Ionescu & Frohman 2006 — continuous CJC-1295 stimulation raised trough and mean GH and IGF-I while episodic GH pulses still occurred (not pure flat “GH bleed” only). trial

Doses people talk about 17

  • With DAC — community weekly: Common discussion band ~1,000–2,000 mcg (1–2 mg) per injection, ~1× weekly; some run ~1–2× weekly. forum
  • With DAC — lower / conservative talk: Some charts and clinics discuss ~300–600 mcg once or twice weekly as a lower starting band; less standardized than 1–2 mg weekly lore. forum
  • With DAC — weight-based bro math: Rough conversion talk maps 30 mcg/kg ≈ 2–2.5 mg for a ~70–80 kg adult once weekly — still not a validated performance protocol. forum
  • No DAC / Mod GRF 1-29 — per pulse: ~100–300 mcg subcutaneous is the standard community band; 100 mcg and 200 mcg are the most cited starting/standard amounts. forum
  • No DAC — frequency: 1–3× daily common; minimum often once pre-bed; aggressive runs add AM fasted and/or post-workout. forum
  • No DAC + Ipamorelin same syringe: Classic 1:1 stack ~100/100 mcg or ~200/200 mcg per injection; many stay 100–300 mcg of each per pulse. forum
  • Ipa-heavy variants: Some logs run Ipamorelin ~150–300 mcg with CJC no-DAC ~100–200 mcg when hunger/side profile allows — ratio debates are common. forum
  • DAC + separate Ipamorelin: Weekly DAC (e.g. ~1–2 mg) plus daily or multi-daily Ipamorelin ~100–300 mcg — convenience hybrid; pulse purists often dislike it. forum
  • Bedtime-first titration: Many start one evening empty-stomach dual dose for 1–2 weeks, then add morning and/or PWO if tolerated. forum
  • Food timing ritual: Empty stomach ~30–60+ minutes (some say ≥90 min after food, wait ~20–30+ min before carbs/fats) claimed to protect the GH pulse from insulin/glucose blunting. forum
  • Don't swap forms 1:1: Weekly DAC milligrams ≠ sum of daily no-DAC micrograms; pharmacokinetics and GH pattern differ. forum
  • Don’t mix 2026 charts: Nightly no-DAC 100–300 mcg ≠ weekly DAC ~1–2 mg. Copying 100/100 onto a DAC vial is the naming-trap dose error. forum
  • No-DAC extra camps: Bedtime only; AM+PM; 2–3× with Ipamorelin; 5-on/2-off. DAC extra camps: 1×/week vs 2×/week vs “low” 300–600 mcg 1–2×/week. forum
  • Blend reconstitution math lives on the pair card: 5/5 and 10/10 1:1 vials are almost always no-DAC in research-chem talk. Total-blend mcg ≠ each-peptide mcg. forum
  • Blend vials (5 mg / 5 mg or 10 mg / 10 mg): Premixed 1:1 no-DAC CJC + Ipamorelin; total blend per pin often discussed ~200–500 mcg combined (e.g. 100+100 or 200+200), 1–3× daily. Vendor ratios can differ — always map label mass. forum
  • Clinical DAC (Teichman 2006): Single SC cohorts used 30, 60, 125 or 250 mcg/kg. Repeated cohorts used 20 or 30 mcg/kg on days 0, 7 and 14, or 30 or 60 mcg/kg on days 0 and 14. Mean single-dose half-lives were 5.8–8.1 days. Fixed-mg forum charts are not trial protocols. trial
  • Framing: Research/community discussion ranges only — not medical advice, not prescriptions, not FDA dosing. forum

How it may feel 10

  • Days 1–3: Often quiet systemically; injection-site warmth/redness possible; bedtime stacks may bring vivid dreams same night. forum
  • Days 1–7: Sleep quality and dream intensity are the most common early reports; physique usually unchanged. forum
  • Weeks 1–2: Morning recovery / less next-day beat-up feel for some; mild facial/hand puffiness can appear, more on DAC or higher exposure. forum
  • Weeks 3–4: Sleep and recovery talk becomes more consistent if the protocol “works”; joint stiffness or nonspecific aches possible as GH/IGF-1 climbs. forum
  • Weeks 6–8: First window where leaner/harder look anecdotes appear — highly confounded by diet, training, water, and co-stacks. anecdote
  • Months 2–3: Common bloodwork reassess window (IGF-1, fasting glucose/A1c interest) for IGF-1-focused users; DAC vs no-DAC strategy check if results stall. forum
  • Months 3–4+: Longer open-ended DAC or continuous no-DAC runs become lifestyle protocols; evidence for sustained athletic superiority thins. forum
  • No change by ~4–6 weeks: Community checklist — confirm DAC vs no-DAC label, empty-stomach timing, GHRP co-use, sleep, calories — before escalating mcg. forum
  • 2026 first nights (no-DAC): Sleep/dreams if bedtime + empty stomach; little daytime buzz. DAC is quieter acutely and more “water/IGF-1 weeks” than “slept harder tonight.” forum
  • Fed no-DAC pin: Same restless/hot bedtime reports as the blend when insulin is still up. forum

Around the dose 8

  • Clock: Night, usually with ipamorelin, empty stomach. forum
  • vs DAC: No-DAC / Mod GRF is a daily night pulse. DAC is multi-day — don’t copy nightly no-DAC habits onto DAC. forum
  • Sleep: The pairing. Night pin, then actually sleep. forum
  • Training: Next-day lifting stays; this is not a gym-bag pin. forum
  • Empty-stomach night pin (no-DAC): ~2–3 hours after food, then sleep — 2026 X still repeats insulin-blunts-the-pulse. forum
  • Split vs bedtime: No-DAC can split AM fasted + night. DAC is multi-day — food timing is argued less; weekly calendar matters more. forum
  • After (no-DAC): Delay carbs. Hunger is usually blamed on the GHRP partner. forum
  • Label check before the pin: If the vial says DAC, do not run a nightly no-DAC ritual. forum

Cycles people discuss 10

  • No-DAC + GHRP common block: 8–12 weeks on is the most repeated community cycle length for recomp/recovery goals. forum
  • Longer no-DAC blocks: 12–16 weeks on appears in some guides before a break; not standardized. forum
  • Time off after no-DAC block: Often ~4 weeks off after 8–12 weeks on; some run equal on/off (e.g. 8 on / 8 off in physician-protocol talk). Practices vary widely. forum
  • 5-on / 2-off: Popular no-DAC schedule — pin weekdays, skip weekends for cost, convenience, or theoretical desensitization reduction. forum
  • DAC style: Some run weekly DAC for months for IGF-1 convenience; others prefer shorter 8–12 week blocks over continuous flat elevation. forum
  • Short probe: 4–6 weeks to test sleep response and tolerance before committing longer. forum
  • Re-runs: Seasonal restarts around cut/bulk or when sleep/recovery dips; long-term multi-year safety data essentially absent. forum
  • Desensitization debate: Forum lore argues continuous DAC “GH bleed” may desensitize more than pulsatile no-DAC + GHRP — mechanistic opinion, not a settled head-to-head RCT. forum
  • No PCT analog: Not treated like AAS; no universal post-cycle SERM protocol — just time off and lifestyle. forum
  • 2026 IGF-1 check is more a DAC habit: Steadier elevation is easier to see on a lab than nightly no-DAC pulses. forum

Timing 10

  • No-DAC / Mod GRF estimate: Around 25–30 minutes is repeated in community discussion, but no human clearance study establishing that figure was verified here. Frequent use and GHRP co-pulses are reported practices, not requirements demonstrated by that estimate. forum
  • Timing hierarchy: Pre-sleep empty stomach dominates; AM fasted and post-workout added for extra daily GH exposure on no-DAC protocols. forum
  • Why stack GHRH + GHRP: Different receptors (GHRH-R vs ghrelin/GHS-R1a) — community and older literature treat simultaneous dual stimulation as synergistic for pulse amplitude. forum
  • Downstream markers: IGF-1 bloodwork weeks into a DAC run is the usual objective check; no-DAC effects on trough IGF-1 are milder/harder to see. forum
  • DAC half-life (human): Estimated ~5.8–8.1 days after SC administration in healthy adults. Weekly or twice-weekly community schedules are reported separately; half-life alone does not validate them. trial
  • Sermorelin comparison: Unmodified GRF 1-29 half-life often cited ~5–10+ minutes; Mod GRF’s substitutions extend usable activity somewhat but still short. trial
  • DAC single-dose GH: Mean GH elevated ~2–10× for ≥6 days after one subq dose in healthy adults. trial
  • DAC single-dose IGF-1: Mean IGF-I elevated ~1.5–3× for ~9–11 days after one dose. trial
  • DAC multi-dose IGF-1: Mean IGF-I remained above baseline up to ~28 days after multiple doses in the same program. trial
  • Pulse vs plateau framing: No-DAC ≈ short pulses (hours); DAC ≈ multi-day elevation with preserved pulses in formal study — bro talk still calls DAC a flatter “GH bleed.” trial

More on what it is 12

  • No-DAC vs DAC: Bro rule of thumb: no-DAC = pulse with GHRP; DAC = longer GH bleed / different side lore. Don’t mix charts. forum
  • Two products under one name: “CJC-1295 with DAC” (true long-acting CJC-1295 / DAC:GRF) vs “CJC-1295 no DAC” which is community slang for Modified GRF 1-29 (Mod GRF 1-29). They are not interchangeable. forum
  • Why people use it: Sleep, recovery, lean-mass / fat-loss “assist,” and IGF-1 elevation talk — almost always paired with a GHRP (especially Ipamorelin). forum
  • Not GH / not a steroid: Does not replace somatropin; DAC and no-DAC are not 1:1 dose-swappable by weekly totals. forum
  • What it is: Synthetic GHRH (growth hormone–releasing hormone) analog based on GRF 1-29 / sermorelin backbone, modified for longer activity. Research peptide — not FDA-approved for body composition, sleep, or anti-aging. trial
  • DAC chemistry: The Drug Affinity Complex (Nε-maleimidopropionyl-Lysine linker) covalently binds serum albumin after injection. Healthy-adult SC DAC studies measured mean half-lives of 5.8–8.1 days; the often-repeated ~30-minute no-DAC estimate is not a comparator established by those studies. trial
  • Four stabilizing substitutions (both forms share the Mod GRF core): Positions 2, 8, 15, and 27 (D-Ala2, Gln8, Ala15, Leu27 vs native sermorelin) resist DPP-IV cleavage better than unmodified GRF 1-29. trial
  • Naming trap: Wikipedia and doping/forensic literature stress that papers and vendors often falsely equate CJC-1295 with Mod GRF 1-29; only the DAC form is classical CJC-1295. trial
  • Evidence honesty: Human PK/PD for DAC form (Teichman 2006, Ionescu/Frohman 2006); athletic and bodycomp outcomes are overwhelmingly community/anecdote, not large RCTs. trial
  • 2026 compounding status: CJC-1295 (all nominated forms, DAC and no-DAC) is not on the 503A bulks list. Nominations withdrawn 2024; December 4, 2024 PCAC voted against inclusion (FDA minutes: 0 yes / 13 no on free-base). Not in the July 2026 PCAC seven. trial
  • FDA safety note (withdrawn-nomination list): increased heart rate and systemic vasodilatory reaction; limited clinical data; immunogenicity / characterization concerns. trial
  • Mechanism framing: GHRH pathway amplifies pituitary GH pulses (or sustained elevation with DAC); still requires intact pituitary somatotrophs — not exogenous rGH. trial

Stacks 12

  • CJC no-DAC + Ipamorelin: Default dual stack and the most common premixed blend on research markets; 1:1 mcg pulses 1–3× daily. forum
  • CJC with DAC + Ipamorelin: Weekly long-acting GHRH + daily GHRP hybrid for fewer pins; pulse purists often prefer pure no-DAC dual dosing. forum
  • No-DAC + GHRP-2: Older high-amplitude stack; more cortisol/prolactin and side talk than Ipamorelin. forum
  • No-DAC + GHRP-6: Strong GH pulse with notable hunger — cut-unfriendly for many. forum
  • No-DAC + Hexarelin: Discussed for strong pulses but more receptor desensitization / cortisol concern in forum lore. forum
  • + BPC-157 / TB-500 (“Wolverine” adjacency): “Recover + sleep + heal” lifestyle stacks — heavy confounding; not a formal GH protocol. forum
  • vs MK-677 (ibutamoren): Oral ghrelin-mimetic alternative or add-on; more water retention, appetite, and fasting-glucose talk for many; continuous elevation vs inject pulses. forum
  • vs Tesamorelin: Tesamorelin has FDA branding (Egrifta) for HIV visceral fat; CJC/Ipa is cheaper gray-market GHRH culture with less VAT-specific trial packaging. forum
  • vs Sermorelin: Clinic-friendly short GHRH; Mod GRF/CJC no-DAC treated as “upgraded sermorelin” in bro science. forum
  • vs exogenous HGH: Stacks sometimes bridge or replace low-dose GH; outcomes and side profiles still differ from pharmacologic rGH. forum
  • Sleep hygiene co-stack: Dark room, fixed bedtime, late-carb control often co-credited when sleep results look good. forum
  • Avoid double GHRH: Running DAC + no-DAC + sermorelin together is generally seen as redundant and side-amplifying without clear upside. forum

Access talk 5

  • 2026 shelves: some 503A pharmacies still fill (risk-tolerance talk), wellness blends labeled “CJC-1295” that usually mean no-DAC, and RUO DAC vs no-DAC vials. Ask which molecule, not just the brand string. forum
  • Not on the July 2026 PCAC seven. trial
  • December 4, 2024 PCAC: FDA proposed not listing CJC-1295 free base, acetate, and DAC forms (free base / acetate / TFA). Minutes record 0 yes / 13 no on placing free-base CJC-1295 on the 503A bulks list. Public writeups treat the related forms as the same no-list outcome; this card does not invent the other tallies. trial
  • Sept 2024: Nominations withdrawn; removed from 503A Category 2 ~27 Sept 2024. Withdrawal ≠ approval to compound. trial
  • FDA withdrawn-nomination safety text: immunogenicity / impurity characterization; increased heart rate and systemic vasodilatory reaction; limited clinical data. trial

Labs people mention 4

  • IGF-1 is the DAC scoreboard in those threads — multi-day elevation is what Teichman-style PK would predict; no-DAC bedtime pulses may barely move a morning trough. forumtrial
  • Glucose: longer DAC runs get more fasting-glucose / A1c talk than a single nightly no-DAC pin. forum
  • Same-lab serial IGF-1 plus age-adjusted range; chasing a forum “200–300 ng/mL sweet spot” is lore, not a label. forum
  • If IGF-1 explodes on “CJC 100 mcg daily”: people suspect a DAC vial was sold as no-DAC, or a stack (MK-677 / rGH) is doing the work. forum

Storage notes 3

  • No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
  • Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum
  • DAC vs no-DAC identity first: Weekly milligrams vs daily micrograms. Blend 5/5 math is a no-DAC convenience format — still not a mix SOP here. forum

Watch for 17

  • Water retention / edema: Transient puffiness (hands, face, ankles) or softer look — more discussed on DAC and higher cumulative GH/IGF-1 exposure. forum
  • Joint / muscle aches: Stiffness, arthralgia-like feel, or nonspecific aches in logs and GH-elevation context. forum
  • Flush / headache / tingle: Short-lived flush, headache, or extremity paresthesias (tingling/numbness) in a subset — sometimes linked to fluid shifts. forum
  • Sleepiness / grogginess: Some get next-morning lethargy; others only report better sleep — split responses. anecdote
  • Increased hunger: Milder than GHRP-6; more often blamed on the GHRP partner than on CJC alone. forum
  • Carpal-tunnel-like symptoms: Occasional hand numbness/tingling talk at higher GH-axis exposure — classic somatropin-adjacent pattern. forum
  • Cancer / mitogenic caution: Theoretical concern with active malignancy or high-risk history because GH/IGF-1 signaling can be growth-promoting — standard secretagogue warning, not a CJC-specific trial endpoint. forum
  • Source / mislabel risk: DAC vs no-DAC swaps, underdosed vials, contamination, and banned-substance doping risk are structural gray-market problems — COA talk is common but not proof. forum
  • Pregnancy / unknowns: No adequate safety data for pregnancy or breastfeeding in community or discontinued clinical programs. forum
  • Water / carpal / glucose: Louder on DAC and on no-DAC multi-pulse stacks. Hand tingle and fasting glucose are the 2026 “cut dose” posts. forum
  • Injection site: Redness, swelling, itch, warmth, or discomfort — most common trial and community complaint; worse with same-site reuse. trial
  • Glucose / insulin sensitivity: GH can antagonize insulin action — community and clinical GH literature flag fasting glucose / metabolic-risk monitoring, especially longer DAC runs. trial
  • ConjuChem trial halt (2006): Phase II HIV lipodystrophy program for CJC-1295 (DAC:GRF) halted after a participant death in Argentina; attending physician judged most likely unrelated (asymptomatic CAD / plaque rupture), but development stopped as precaution. Causality never established as drug-related in public summaries. trial
  • Trial tolerability (healthy adults): Teichman 2006 reported no serious adverse reactions in the healthy-adult PK program; relatively well tolerated especially at 30–60 mcg/kg — not a long-term athlete safety guarantee. trial
  • Not FDA-approved for bodycomp: No approved indication for muscle, fat loss, sleep, or anti-aging; remains research / gray-market culture. trial
  • Long-term data gap: Multi-year controlled safety and athletic outcome data do not exist; continuous IGF-1 elevation strategies remain experimental. trial
  • PCAC / FDA cardiac-adjacent talk: Increased heart rate and vasodilatory reaction are what 2024–26 compounding writeups repeat from FDA’s CJC-1295 note — not a new gym RCT. trial

Updated: 2026-09-01

Evidence mix Mostly community / anecdote tags Full: every bullet (trial + community). Use Scan for a faster bro-science read.
↑ Back to top

All STUDresearch topics →